$TSHA
Taysha Gene Therapies, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023063734 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $3.604M $4.746M
YoY Change 44.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.719M $8.590M
YoY Change -8.47% -1.07%
% of Gross Profit
Research & Development $12.68M $11.79M
YoY Change -8.51% -28.06%
% of Gross Profit
Depreciation & Amortization $366.0K $300.0K
YoY Change 0.55% 0.0%
% of Gross Profit
Operating Expenses $19.40M $21.00M
YoY Change -8.49% -16.26%
Operating Profit -$16.25M
YoY Change -35.19%
Interest Expense $1.208M $1.471M
YoY Change -302.35% 18.53%
% of Operating Profit
Other Income/Expense, Net $64.18M -$100.8M
YoY Change -1069716.67% 8078.18%
Pretax Income $47.74M -$117.1M
YoY Change -185.68% 345.09%
Income Tax
% Of Pretax Income
Net Earnings $47.74M -$117.1M
YoY Change -185.68% 345.08%
Net Earnings / Revenue 1324.67% -2467.07%
Basic Earnings Per Share -$0.93
Diluted Earnings Per Share $0.23 -$0.93
COMMON SHARES
Basic Shares Outstanding 187.0M 64.47M
Diluted Shares Outstanding 125.7M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.9M $164.3M
YoY Change 63.79% 378.92%
Cash & Equivalents $143.9M $164.3M
Short-Term Investments
Other Short-Term Assets $292.0K $404.0K
YoY Change -34.82% 6.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $149.9M $171.8M
YoY Change 55.44% 299.53%
LONG-TERM ASSETS
Property, Plant & Equipment $10.83M $11.17M
YoY Change -27.65% -82.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $304.0K $304.0K
YoY Change -76.9% -75.58%
Total Long-Term Assets $22.86M $23.96M
YoY Change -23.43% -65.0%
TOTAL ASSETS
Total Short-Term Assets $149.9M $171.8M
Total Long-Term Assets $22.86M $23.96M
Total Assets $172.7M $195.8M
YoY Change 36.79% 75.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.366M $7.520M
YoY Change -41.84% -50.69%
Accrued Expenses $11.21M $12.60M
YoY Change -38.72% -29.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $354.0K $300.0K
YoY Change
Total Short-Term Liabilities $36.76M $180.5M
YoY Change -41.46% 444.53%
LONG-TERM LIABILITIES
Long-Term Debt $40.51M $38.55M
YoY Change 6.69% 2.05%
Other Long-Term Liabilities $1.577M $3.832M
YoY Change -61.82% -2.59%
Total Long-Term Liabilities $42.09M $42.38M
YoY Change -0.03% 1.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.76M $180.5M
Total Long-Term Liabilities $42.09M $42.38M
Total Liabilities $97.79M $244.9M
YoY Change -21.97% 144.05%
SHAREHOLDERS EQUITY
Retained Earnings -$513.0M -$560.7M
YoY Change 27.8% 62.08%
Common Stock $2.000K $2.000K
YoY Change 100.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.94M -$49.11M
YoY Change
Total Liabilities & Shareholders Equity $172.7M $195.8M
YoY Change 36.79% 75.63%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $47.74M -$117.1M
YoY Change -185.68% 345.08%
Depreciation, Depletion And Amortization $366.0K $300.0K
YoY Change 0.55% 0.0%
Cash From Operating Activities -$16.12M -$17.95M
YoY Change -212.89% -37.36%
INVESTING ACTIVITIES
Capital Expenditures $17.00K $0.00
YoY Change -99.26% -100.0%
Acquisitions
YoY Change
Other Investing Activities $7.000K -$3.490M
YoY Change -111.48% 249.0%
Cash From Investing Activities -$10.00K -$3.490M
YoY Change -99.58% 15.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.248M 140.6M
YoY Change -110.2% -54607.75%
NET CHANGE
Cash From Operating Activities -16.12M -17.95M
Cash From Investing Activities -10.00K -3.490M
Cash From Financing Activities -4.248M 140.6M
Net Change In Cash -20.37M 119.2M
YoY Change -138.03% -473.25%
FREE CASH FLOW
Cash From Operating Activities -$16.12M -$17.95M
Capital Expenditures $17.00K $0.00
Free Cash Flow -$16.13M -$17.95M
YoY Change -234.81% -32.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001806310
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201602Member
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201602Member
CY2022Q3 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201602Member
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q3 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q3 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#Liabilities
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39536
dei Entity Registrant Name
EntityRegistrantName
Taysha Gene Therapies, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3199512
dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Pegasus Park Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 1430
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
dei City Area Code
CityAreaCode
214
dei Local Phone Number
LocalPhoneNumber
612-0000
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
TSHA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
us-gaap Variable Lease Cost
VariableLeaseCost
729000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
186960193
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
186960193
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164278000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87880000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5529000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2023Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
2000000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
171807000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96417000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2637000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11169000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9852000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10943000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
304000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1316000
CY2023Q3 us-gaap Assets
Assets
195769000
CY2022Q4 us-gaap Assets
Assets
126276000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7520000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10946000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13638000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18759000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33557000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
140534000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
180451000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62790000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2951000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
38548000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37967000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19101000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20440000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3832000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4130000
CY2023Q3 us-gaap Liabilities
Liabilities
244883000
CY2022Q4 us-gaap Liabilities
Liabilities
125327000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
186960193
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63207507
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63207507
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
511632000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
402389000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-560748000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401441000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-49114000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
195769000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126276000
CY2023Q3 us-gaap Revenues
Revenues
4746000
us-gaap Revenues
Revenues
11847000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11791000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16774000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44096000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78462000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8589000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8683000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23328000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30019000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
616000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
616000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
20996000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
25457000
us-gaap Operating Expenses
OperatingExpenses
68040000
us-gaap Operating Expenses
OperatingExpenses
108481000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16250000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-25457000
us-gaap Operating Income Loss
OperatingIncomeLoss
-56193000
us-gaap Operating Income Loss
OperatingIncomeLoss
-108481000
CY2023Q3 tsha Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
100456000
tsha Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
100456000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1109000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1651000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
50000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1471000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1078000
us-gaap Interest Expense
InterestExpense
4285000
us-gaap Interest Expense
InterestExpense
2493000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-100837000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1070000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-103114000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2455000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-117087000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26527000
us-gaap Net Income Loss
NetIncomeLoss
-159307000
us-gaap Net Income Loss
NetIncomeLoss
-110936000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125700799
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125700799
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40937808
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40937808
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84630796
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84630796
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39761764
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39761764
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37114000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2040000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
18000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-117087000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-49114000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
32507000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4470000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
253000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26527000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10703000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5937000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
68000
us-gaap Net Income Loss
NetIncomeLoss
-159307000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-49114000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95383000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14172000
tsha Payment Of Sales Commissions And Other Offering Costs
PaymentOfSalesCommissionsAndOtherOfferingCosts
392000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11609000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
253000
us-gaap Net Income Loss
NetIncomeLoss
-110936000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10703000
us-gaap Profit Loss
ProfitLoss
-159307000
us-gaap Profit Loss
ProfitLoss
-110936000
us-gaap Depreciation
Depreciation
1005000
us-gaap Depreciation
Depreciation
810000
tsha Research And Development License Expense
ResearchAndDevelopmentLicenseExpense
3500000
tsha Research And Development License Expense
ResearchAndDevelopmentLicenseExpense
1250000
us-gaap Share Based Compensation
ShareBasedCompensation
5937000
us-gaap Share Based Compensation
ShareBasedCompensation
13940000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100456000
tsha Issuance Costs For Pre Funded Warrant Liability
IssuanceCostsForPreFundedWarrantLiability
2567000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
616000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
908000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1031000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-581000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-616000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4008000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1980000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1065000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3217000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-4260000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-8576000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11847000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56901000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103102000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3500000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4250000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3852000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18310000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-10000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7342000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22560000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11640000
tsha Proceeds From Issuance Of Common Stock And Prefunded Warrants From Private Placement Net Of Placement Agent Commissions And Other Offering Costs
ProceedsFromIssuanceOfCommonStockAndPrefundedWarrantsFromPrivatePlacementNetOfPlacementAgentCommissionsAndOtherOfferingCosts
140713000
tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
387000
tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
319000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
68000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
253000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-253000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-709000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
140641000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10865000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
76398000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-114797000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90517000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
166915000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36943000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164278000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34306000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
2637000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
166915000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36943000
us-gaap Interest Paid Net
InterestPaidNet
3665000
us-gaap Interest Paid Net
InterestPaidNet
1758000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
45000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
3366000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
23035000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
423000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
40000
tsha Issuance Of Warrants In Connection With Private Placement
IssuanceOfWarrantsInConnectionWithPrivatePlacement
252000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-560700000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the initial public offering ("IPO") (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the measurement of impairment of long-lived assets, the fair value of the warrant liability, and the allocation of consideration received in connection with the Astellas Transactions (as defined below) at contract inception. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
600000
CY2023Q3 tsha Derecognized Build To Suit Lease Asset Presented In Property Plant Equipment
DerecognizedBuildToSuitLeaseAssetPresentedInPropertyPlantEquipment
26300000
CY2023Q3 tsha Derecognized Build To Suit Lease Liability
DerecognizedBuildToSuitLeaseLiability
26500000
CY2023Q3 tsha Deferred Rent Liabiilities And Tenant Improvement Allowances
DeferredRentLiabiilitiesAndTenantImprovementAllowances
700000
CY2023Q3 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78462000
us-gaap Interest Expense
InterestExpense
2493000
us-gaap Net Income Loss
NetIncomeLoss
-110936000
us-gaap Depreciation
Depreciation
810000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1031000
tsha Increase Decrease In Accrued Expense And Other Current Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherCurrentLiabilities
-8576000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-709000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
23035000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16774000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1078000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-26527000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
150514000
CY2023Q3 tsha Ssi Warrants
SsiWarrants
701000
CY2023Q3 tsha Pre Funded Warrants
PreFundedWarrants
139833000
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
140534000
CY2023Q3 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
2672000
CY2022Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
4840000
CY2023Q3 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
1392000
CY2022Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2119000
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
724000
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
724000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
337000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
388000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
404000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
466000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5529000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13812000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16605000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2643000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1642000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11169000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2022Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
36400000
CY2022Q4 tsha Construction In Progress And Finance Lease Right Of Use Asset
ConstructionInProgressAndFinanceLeaseRightOfUseAsset
26300000
CY2023Q3 us-gaap Depreciation
Depreciation
300000
CY2022Q3 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
1000000
us-gaap Depreciation
Depreciation
800000
CY2023Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-600000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-600000
CY2023Q3 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
5699000
CY2022Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8190000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2745000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2519000
CY2023Q3 tsha Lease Liability Current
LeaseLiabilityCurrent
1538000
CY2022Q4 tsha Lease Liability Current
LeaseLiabilityCurrent
1521000
CY2023Q3 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1359000
CY2022Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1473000
CY2023Q3 tsha Accrued Severance
AccruedSeverance
992000
CY2022Q4 tsha Accrued Severance
AccruedSeverance
1463000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
579000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
390000
CY2023Q3 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
45000
CY2022Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
2081000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
681000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
650000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13638000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
696000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
794000
us-gaap Operating Lease Cost
OperatingLeaseCost
2088000
us-gaap Operating Lease Cost
OperatingLeaseCost
2079000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
243000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
229000
us-gaap Variable Lease Cost
VariableLeaseCost
617000
CY2023Q3 us-gaap Lease Cost
LeaseCost
939000
CY2022Q3 us-gaap Lease Cost
LeaseCost
1023000
us-gaap Lease Cost
LeaseCost
2817000
us-gaap Lease Cost
LeaseCost
2696000
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M17D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M17D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y11M19D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y5M12D
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1052
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1051
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0779
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0772
us-gaap Operating Lease Payments
OperatingLeasePayments
2109000
us-gaap Operating Lease Payments
OperatingLeasePayments
847000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
686000
CY2023Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
114000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2810000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
454000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2910000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
454000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2485000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
399000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2577000
CY2023Q3 tsha Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
19721000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
31189000
CY2023Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1421000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10895000
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
242000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
20294000
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1179000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1193000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
345000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19101000
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
834000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
20294000
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1179000
CY2022Q4 tsha Probability Of An Option Exercise
ProbabilityOfAnOptionExercise
0.50
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3100000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3100000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18800000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2021Q3 tsha Percentage Of Annual Default Interest Rate
PercentageOfAnnualDefaultInterestRate
0.05
CY2023Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1400000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
4200000
CY2022Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1100000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2500000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6667000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
13333000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1452000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
38548000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40937808
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40937808
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1067682
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
3160375
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
-5241357
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
-3586442
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2573142
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2040000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4470000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5937000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13940000
CY2023Q3 tsha Common Stock And Warrants Fair Value Disclosure
CommonStockAndWarrantsFairValueDisclosure
149953
tsha Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
100456000
CY2023Q3 tsha Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
140534000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-117087000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26527000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-159307000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-110936000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125700799
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125700799
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84630796
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84630796
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39761764
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39761764
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.79
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53276530
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5955191
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000

Files In Submission

Name View Source Status
0000950170-23-063734-index-headers.html Edgar Link pending
0000950170-23-063734-index.html Edgar Link pending
0000950170-23-063734.txt Edgar Link pending
0000950170-23-063734-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img38651418_0.jpg Edgar Link pending
img38651418_1.jpg Edgar Link pending
img38651418_10.jpg Edgar Link pending
img38651418_2.jpg Edgar Link pending
img38651418_3.jpg Edgar Link pending
img38651418_4.jpg Edgar Link pending
img38651418_5.jpg Edgar Link pending
img38651418_6.jpg Edgar Link pending
img38651418_7.jpg Edgar Link pending
img38651418_8.jpg Edgar Link pending
img38651418_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-20230930.htm Edgar Link pending
tsha-20230930.xsd Edgar Link pending
tsha-ex10_2.htm Edgar Link pending
tsha-ex31_1.htm Edgar Link pending
tsha-ex31_2.htm Edgar Link pending
tsha-ex32_1.htm Edgar Link pending
tsha-ex32_2.htm Edgar Link pending
tsha-20230930_cal.xml Edgar Link unprocessable
tsha-20230930_def.xml Edgar Link unprocessable
tsha-20230930_lab.xml Edgar Link unprocessable
tsha-20230930_pre.xml Edgar Link unprocessable
tsha-20230930_htm.xml Edgar Link completed